Study Evaluating Theranostic PET Imaging for Tumor Detection and Staging Using Novel and Established Tracers in Patients with Solid Tumors

What this Trial Is About

This research aims to collect detailed data on the use of theranostic PET imaging in patients with solid tumors. The study evaluates how different PET tracers detect tumor regions and their impact on tumor staging, restaging, and therapy planning. It investigates the relationship between PET signal intensity and the expression of molecular targets in tumor tissues. Patients undergoing theranostic PETCT or PETMRI as part of their routine clinical care receive imaging with novel or established PET tracers. These tracers include several agents with theranostic potential, used for tumor detection and assessment both at initial diagnosis and before treatment decisions. The study gathers data on detection rates, positive predictive value, reproducibility, and changes in clinical management based on imaging results. Participants will have their PET images analyzed alongside histopathology, clinical follow-up, and conventional imaging data. Researchers measure how well PET uptake correlates with molecular target expression and tumor detection accuracy. The study also evaluates the impact of PET findings on staging and treatment plans. This observational study involves data collection during routine care, with follow-up assessments over 12 months to monitor outcomes and image reproducibility.

Theranostic PET for Target Validation and Tumor Detection